Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NM-3 是一种可口服的抗血管生成的抑制剂,具有抗肿瘤活性。NM-3在体外和体内可当作辐射调节剂使用。NM-3抑制血管内皮生长因子(VEGF),从而抑制内皮细胞的增殖。NM-3与活性氧的机制诱导细胞凋亡有关。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,330 | 现货 | ||
5 mg | ¥ 3,330 | 现货 | ||
10 mg | ¥ 4,850 | 现货 | ||
25 mg | ¥ 7,630 | 现货 | ||
50 mg | ¥ 9,870 | 现货 | ||
100 mg | ¥ 13,800 | 现货 | ||
500 mg | ¥ 27,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,930 | 现货 |
产品描述 | NM-3 is an orally available anti-angiogenic inhibitor with anti-tumour activity.NM-3 is used as a radiation modulator in vitro and in vivo.NM-3 inhibits vascular endothelial growth factor (VEGF), thereby inhibiting the proliferation of endothelial cells. This inhibits the proliferation of endothelial cells. NM-3 is associated with a mechanism of apoptosis induction by reactive oxygen species. |
体外活性 | NM-3 (100 ng/ml) is cytotoxic to human umbilical vein endothelial cells (HUVECs) but not to Lewis lung carcinoma (LLC) cells nor Seg-1, esophageal adenocarcinoma cells, in clonogenic survival assays (1,000 ng/ml ; 4h).[1] |
体内活性 | C57BL/6 female mice bearing LLC tumors were given injections for 4 consecutive days with NM-3 (25 mg/kg/day) and treated with IR (20 Gy) for 2 consecutive days. Combined treatment with NM-3 and IR significantly reduced mean tumor volume compared with either treatment alone. An increase in local tumor control was also observed in LLC tumors in mice receiving NM-3/IR therapy. When athymic nude mice bearing Seg-1 tumor xenografts were treated with NM-3 (100 mg/kg/day for 4 days) and 20 Gy (four 5 Gy fractions), significant tumor regression was observed after combined treatment (NM-3 and IR) compared with IR alone. Importantly, no increase in systemic or local tissue toxicity was observed after combined treatment (NM-3 and IR) when compared with IR alone. The bioavailability and nontoxic profile of NM-3 suggests that the efficacy of this agent should be tested in clinical radiotherapy.[1] |
别名 | NM-3, isocoumarin, NM 3, Isocoumarin NM-3, NM3 |
分子量 | 264.23 |
分子式 | C13H12O6 |
CAS No. | 181427-78-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (104.08 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.7846 mL | 18.9229 mL | 37.8458 mL | 94.6145 mL |
5 mM | 0.7569 mL | 3.7846 mL | 7.5692 mL | 18.9229 mL | |
10 mM | 0.3785 mL | 1.8923 mL | 3.7846 mL | 9.4615 mL | |
20 mM | 0.1892 mL | 0.9461 mL | 1.8923 mL | 4.7307 mL | |
50 mM | 0.0757 mL | 0.3785 mL | 0.7569 mL | 1.8923 mL | |
100 mM | 0.0378 mL | 0.1892 mL | 0.3785 mL | 0.9461 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NM-3 181427-78-1 Apoptosis Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species isocoumarin NM 3 Isocoumarin NM-3 NM3 Inhibitor inhibitor inhibit